Send to printer »

GEN News Highlights : Jul 21, 2008

Gamida Obtains Rights to Amgen Cytokines to Produce Stem Cell Cancer Drug

StemEx is being tested in Phase III trials against leukemia and lymphoma.

Gamida Cell will use a number of cytokines from Amgen to manufacture StemEx for its pivotal registration study and subsequent commercialization. The product is being developed for hematological malignancies by Gamida Cell in a joint venture with Teva Pharmaceutical.

Under the terms of the nonexclusive license agreement, Amgen will receive a minority equity interest in Gamida Cell in addition to royalties from sales related to hematological indications.

StemEx is composed of ex vivo expanded cord blood stem/progenitor cells that are transplanted with nonexpanded cells from the same unit. In November 2007, the first patient enrolled in the international, multicenter trial, underwent a StemEx transplant.